Acute myeloid leukemia

Score 6.3 = 5.9 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph2NCT06930352 · Uma Borate · Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
• Ph2NCT07437950 · National Cancer Institute (NCI) · Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
• Ph1NCT06222580 · Uma Borate · SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Score 5.8 = 5 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph3NCT07925190 · Beijing InnoCare Pharma Tech Co., Ltd. · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
• Ph2NCT07743112 · Maxinovel Pty., Ltd. · A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
• Ph1NCT07137637 · Hangzhou Polymed Biopharmaceuticals, Inc. · HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Score 5.5 = 5.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph3NCT07132684 · Institute of Hematology & Blood Diseases Hospital, China · Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
• Ph1/Ph2NCT06611839 · Institute of Hematology & Blood Diseases Hospital, China · Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
• Ph2NCT06635681 · Institute of Hematology & Blood Diseases Hospital, China · Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

Score 4.9 = 4.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 4 of 4 trials are Phase 2+.

• Ph3NCT07925190 · Beijing InnoCare Pharma Tech Co., Ltd. · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
• Ph1/Ph2NCT05133882 · Sunshine Lake Pharma Co., Ltd. · A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
• Ph1/Ph2NCT04501120 · Ascentage Pharma Group Inc. · Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
• Ph3NCT05586074 · Sunshine Lake Pharma Co., Ltd. · HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Score 4.9 = 4.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT04010877 · Shenzhen Geno-Immune Medical Institute · Multiple CAR-T Cell Therapy Targeting AML
• Ph1/Ph2NCT03222674 · Shenzhen Geno-Immune Medical Institute · Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Score 4.7 = 4.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph1/Ph2NCT06548230 · M.D. Anderson Cancer Center · A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
• Ph1/Ph2NCT07053020 · M.D. Anderson Cancer Center · A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
• Ph1/Ph2NCT02392572 · M.D. Anderson Cancer Center · ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

Score 4.6 = 4.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 4 of 4 trials are Phase 2+.

• Ph2NCT07819396 · Fred Hutchinson Cancer Center · Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
• Ph2NCT04994808 · Fred Hutchinson Cancer Center · Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
• Ph1/Ph2NCT03670966 · Fred Hutchinson Cancer Center · 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
• Ph2NCT04195633 · Fred Hutchinson Cancer Center · Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Score 4.5 = 4.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT07356154 · Memorial Sloan Kettering Cancer Center · A Study of Revumenib and Mezigdomide in People With Leukemia
• Ph2NCT07392242 · Memorial Sloan Kettering Cancer Center · A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Score 4.2 = 3.8 leading Phase 2+ trials + 0.5 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph2NCT07228273 · OHSU Knight Cancer Institute · Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
• Ph2NCT06504459 · OHSU Knight Cancer Institute · Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
• Ph1NCT06357182 · OHSU Knight Cancer Institute · Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Score 4.1 = 4.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph2NCT04262843 · City of Hope Medical Center · Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
• Ph2NCT05364762 · City of Hope Medical Center · Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
• Ph2NCT07582172 · City of Hope Medical Center · Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Score 4.1 = 4.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06001385 · Center for International Blood and Marrow Transplant Research · HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
• Ph2NCT07563010 · Center for International Blood and Marrow Transplant Research · Menin-Inhibitor Targeted Maintenance in AML

Score 3.8 = 0.5 leading Phase 2+ trials + 3.3 other trial roles + 0 talks + 0 posters. 1 of 6 trials are Phase 2+.

• Ph1NCT07549464 · M.D. Anderson Cancer Center · Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
• Ph1NCT07780565 · M.D. Anderson Cancer Center · Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome
• Ph1NCT06285890 · M.D. Anderson Cancer Center · Phase I Study of HC-7366 for Acute Myeloid Leukemia
• Ph2NCT04975919 · M.D. Anderson Cancer Center · Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
• Ph1NCT05834244 · M.D. Anderson Cancer Center · A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
• Ph1NCT06445907 · M.D. Anderson Cancer Center · Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Score 3.6 = 2.8 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT07130695 · Virginia Commonwealth University · Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
• Ph2NCT07710534 · Virginia Commonwealth University · Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07862517 · National Cancer Institute (NCI) · Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
• Ph2NCT03289910 · National Cancer Institute (NCI) · Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Score 3.2 = 2.4 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph2NCT07925554 · Peking University People's Hospital · Interferon-α Maintenance in Favorable-Risk AML
• Ph1NCT07617285 · Peking University People's Hospital · Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07478991 · PETHEMA Foundation · Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
• Ph1/Ph2NCT04687761 · PETHEMA Foundation · Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07507760 · PETHEMA Foundation · Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
• Ph1/Ph2NCT04687761 · PETHEMA Foundation · Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07783100 · The First Affiliated Hospital of Xiamen University · Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05554419 · National Cancer Institute (NCI) · Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07604233 · M.D. Anderson Cancer Center · Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07634536 · Stanford University · Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07153497 · National Cancer Institute (NCI) · Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07605949 · UNC Lineberger Comprehensive Cancer Center · Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06954987 · National Cancer Institute (NCI) · Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07925190 · Beijing InnoCare Pharma Tech Co., Ltd. · A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05291390 · Armaceutica, Inc. · Pyronaridine in Acute Myeloid Leukemia (AML)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07572929 · Medical College of Wisconsin · A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06917911 · National Cancer Institute (NCI) · Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07867626 · Rutgers, The State University of New Jersey · Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

Score 2.8 = 1.4 leading Phase 2+ trials + 1.4 other trial roles + 0 talks + 0 posters. 6 of 8 trials are Phase 2+.

• Ph1/Ph2NCT03214562 · M.D. Anderson Cancer Center · Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
• Ph1NCT06616636 · M.D. Anderson Cancer Center · A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
• Ph1/Ph2NCT03471260 · M.D. Anderson Cancer Center · Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
• Ph2NCT03683433 · M.D. Anderson Cancer Center · Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
• Ph2NCT03383575 · M.D. Anderson Cancer Center · Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
• Ph2NCT04493164 · M.D. Anderson Cancer Center · CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
• Ph1NCT07411586 · M.D. Anderson Cancer Center · Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
• Ph1/Ph2NCT04774393 · M.D. Anderson Cancer Center · Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Score 2.8 = 2.2 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 3 of 4 trials are Phase 2+.

• Ph1/Ph2NCT05360160 · M.D. Anderson Cancer Center · A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
• Ph1/Ph2NCT06284486 · M.D. Anderson Cancer Center · A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
• Ph1NCT06769490 · M.D. Anderson Cancer Center · Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
• Ph2NCT02286726 · M.D. Anderson Cancer Center · CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Score 2.8 = 2.7 leading Phase 2+ trials + 0.1 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph1NCT04375631 · Fred Hutchinson Cancer Center · CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
• Ph2NCT07046078 · Fred Hutchinson Cancer Center · Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
• Ph2NCT03399773 · Fred Hutchinson Cancer Center · Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07813390 · Guangdong Second Provincial General Hospital · Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07022678 · Children's Oncology Group · Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06707493 · Massachusetts General Hospital · Ivosidenib as Post-HSCT Maintenance for AML
• Ph2NCT04801797 · Massachusetts General Hospital · Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07748455 · Pakistan Blood and Marrow Transplant (PBMT) Group · HMA-Venetoclax Induction in Newly Diagnosed AML

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06903702 · Memorial Sloan Kettering Cancer Center · A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07392970 · Washington University School of Medicine · Motixafortide for MRD Sensitization in AML

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07735117 · Ruijin Hospital · Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07478991 · PETHEMA Foundation · Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)